Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Bo Mattiasson konsult AB
AB
In liquidation
Org 5591428296
Research and experimental development on biotechnology
· NACE 7211
Est. 2017
1 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on biotechnology
/
Bo Mattiasson konsult AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
Income statement
SEK thousands
Item
2018
2019
2020
Revenue
0
0
0
Staff expenses
—
—
—
EBITDA
−21
−1
−19
Depreciation & amort.
−30
−0
−0
EBIT
−51
−1
−19
Net financials
543
355
—
Profit before tax
493
354
−19
Tax
−0
−0
−0
Net profit
493
354
−19
Balance sheet
SEK thousands
Item
2018
2019
2020
Total assets
563
777
640
Equity
543
726
587
Long-term debt
0
0
0
Short-term debt
21
51
52
Total debt
21
51
52
Financial ratios
5-year trend
EBITDA margin
-1900000.0%
This company
15.8%
Market median
-12025416% vs market
2018
2020
Equity ratio
91.7%
This company
38.2%
Market median
+140% vs market
2018
2020
Return on equity
-3.2%
This company
18.4%
Market median
-117% vs market
2018
2020
Net profit margin
-1900000.0%
This company
8.1%
Market median
-23456890% vs market
2018
2020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2018
2020
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
2018
2020
Annual reports & filings
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via Bolagsverket / SCB · Period 2017-12-01 – 2018-12-31
View
PDF
More on Bo Mattiasson konsult AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
